Virtual Library
Start Your Search
Jianguo Feng
Author of
-
+
P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.16-18 - Role of ERCC1/2 Single Nucleotide Polymorphism (SNP) on Treatment Response in Patients with Lung Cancer Undergoing Radiation Therapy (ID 14476)
16:45 - 18:00 | Author(s): Jianguo Feng
- Abstract
Background
Radiation therapy plays an important role in the treatment of lung cancer. The protein excision-repair cross-comlementation 1 (ERCC1) and protein excision-repair cross-comlementation 2 (ERCC2) are the key enzymes in NER pathway. Studies showed that ERCC1/2 were associated with susceptibility and efficacy of chemotherapy in lung cancer, but the association between ERCC1/2 SNPs and radiotherapy were seldom reported.
a9ded1e5ce5d75814730bb4caaf49419 Method
Eighty-seven peripheral blood samples were collected from patients with NSCLC before they received radiotherapy in our department from November 2014 to October 2017. The peripheral blood leukocyte DNA was isolated and SNP genotypes were detected by competitive allele-specific PCR. Seven SNPs in ERCC1/2 were analyzed. Data was collected both before and after radiotherapy from blood serum. Elisa was used to detect ERCC1 expression. The association between the changes of expression of ERCC1 during radiotherapy and efficacy, risk of RILI and SNPs in ERCC1 was analyzed.
4c3880bb027f159e801041b1021e88e8 Result
ERCC1 re3212961 minor allele A was associated with a better response to radiotherapy in NSCLC patients. Survival analyses showed that G/G genotype had favorable OS than A/A genotype (P=0.012). Cox regression analysis indicated that ERCC1 rs11615 G/G genotype was associated with decreased risk of death. Subgroup analyses indicated that patients with G/G genotype who received high BED radiotherapy had better OS (median not reached vs. 21.5 months, 95%CI：15.3-27.7，P=0.011) and PFS (median not reached vs. 19.9 months, 95%CI：8.6-31.2，P<0.001) than low BED subgroup. There was no significant association between ERCC1/2 SNPs and RILI. The ERCC1 expression in serum was significantly increased after radiotherapy. However, the changes of ERCC1 expression showed no association with efficacy of radiotherapy, risk of RILI or SNPs of ERCC1/2.
8eea62084ca7e541d918e823422bd82e Conclusion
ERCC1 rs3212961 was related with short-term curative efficacy. ERCC1 rs11615 was an independent prognostic factor in NSCLC, which could serve as biomarker, because G/G genotype had favorable OS and PFS, and was associated with decreased risk of death. There was no significant correlation between ERCC1/2 SNPs and RILI. The changes of ERCC1 expression after radiotherapy showed no association with efficacy of radiotherapy, risk of RILI or SNPs of ERCC1/2.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P2.04 - Immunooncology (Not CME Accredited Session) (ID 953)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.04-18 - The Association Between IDO Activity and Clinical Prognosis in Patients with Non-Small Cell Lung Cancer After Radiotherapy (ID 14394)
16:45 - 18:00 | Author(s): Jianguo Feng
- Abstract
Background
Immunity affects the efficacy of radiotherapy and prognosis of patients. indoleamine 2,3-dioxygenase (IDO), a limiting enzyme in the IDO/kynurenine pathway, could converts the tryptophan (T) into kynurenine (K), which promotes immune suppression and assist tumor cells in immune evasion. The aim of this study was to investigate the association between the IDO activity and kynurenine and clinical outcome in non-small cell lung cancer (NSCLC) patients who received radiotherapy.
a9ded1e5ce5d75814730bb4caaf49419 Method
Blood serum K and T in 114 NSCLC patients were measured by high performance liquid chromatography and mass spectrometer in time before and after radiotherapy. The ratio of K: T represents the activity of IDO. Kaplan-Meier curve and log-rank test were performed to evaluated the correlation with Overall survival (OS) or progression-free survival (PFS) and IDO activity. The Cox proportional hazards model was used for univariate and multivariate analyses.
4c3880bb027f159e801041b1021e88e8 Result
On average, both the K and the ratio of K: T were increased after radiotherapy (P<0.001 and P=0.006). The patients with reduced K: T after radiotherapy had better OS than who with increased K: T (not reached vs. 20.2 months，P=0.004). In subgroup of patients who received Stereotactic Body Radiation Therapy (SBRT), patients with reduced K: T after radiotherapy had better OS and PFS than who with increased K: T (median OS: not reached vs. 20.2 months，P=0.008 and median PFS: not reached vs. 10.9 months，P=0.006, respectively). Multivariate analysis also showed that IDO activity was a factor for OS and PFS （HR=6.667，95%CI：1.515~29.411，P=0.012 and HR=5.348，95%CI：1.427~20.000，P=0.013, respectively).
8eea62084ca7e541d918e823422bd82e Conclusion
The change of IDO activity after radiotherapy is associated with prognosis in NSCLC. The patients with reduced IDO activity after radiotherapy had better OS than who with increased. Especially for patients who received SBRT, patients with reduced IDO activity had better OS and PFS than those increased after radiotherapy. IDO is a potential molecular marker of NSCLC to evaluated the prognosis after radiotherapy.
6f8b794f3246b0c1e1780bb4d4d5dc53
